It was almost four years ago that Tilray Brands (NASDAQ: TLRY) announced that it would be merging with low-cost cannabis ...

The launch marks the first medical cannabis products Aphria RX has grown under the medical cannabis cultivation license ...

Detailed price information for Tilray Brands Inc (TLRY-Q) from The Globe and Mail including charting and trades.

Tilray Medical launches its first German-grown cannabis products under a new cultivation license, tapping into Germany's ...

Medical, a division of Tilray Brands, announced the launch of its first commercial German grown medical cannabis flowers from its ...

In July 2024, Tilray’s Aphria RX became the first company to receive a cultivation license under MedCanG, allowing them to produce and manufacture medical cannabis for commercial sale in Germany. The ...

It was almost four years ago that Tilray Brands (NASDAQ: TLRY) announced that it would be merging with low-cost cannabis producer Aphria to create a larger, more dynamic, and global marijuana company.

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its ...

The Beverage business has been beer, though the company will soon introduce THC beverages from industrial hemp in the U.S. The Distribution business, which it picked up when it bought Aphria ...

This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment ...